Response to Levrier re: Human Germline and Heritable Genome Editing: The Global Policy Landscape
By Marcy Darnovsky, Katie Hasson, and Timothy M. Krahn,
The CRISPR Journal
| 02. 19. 2021
In response to: https://www.liebertpub.com/doi/10.1089/crispr.2021.29121.gle
Levrier apparently misunderstands the nature of our project published in The CRISPR Journal in October 2020.1 We identified and reviewed policy documents relevant to human germline and heritable genome editing research in 96 countries. We did not speculate about arguments that might lead legislatures or courts to revise existing policies or adjudicate prospective cases, nor did we attempt to examine each policy in its national or international context. Rather, based on close and careful readings of the identified texts, we categorized countries according to the current permissibility or impermissibility of germline and heritable genome editing. Then, we counted.
We welcome corrections and additions to the data we have compiled, which we plan to keep updated at https://tinyurl.com/HumanGenomeEditingPolicies. Unfortunately, Levrier does not provide appropriate documentation for his challenge to our categorizations regarding human germline and heritable genome editing research in three countries (France, Mexico, and Japan). Instead, he points to a report, unspecified “debates” in the French parliament, and comments on social media. We sometimes used such sources to identify relevant policy documents, but did...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...